LIPAGLYN: Zydus Research Center

 Lipaglyn

Company Name: Zydus Cadila Healthcare Ltd. 

Therapeutic Use: For treating Hypertriglyceridemia and Diabetic dislipidemia. 

Active Constituent: Saroglitazar 

Introduction: 

Lipaglyn is currently approved for prescription medicine in India for treating Hypertriglyceridemia and Diabetic dislipidemia in patient with Type 2 diabetes not controlled by statin. 

Saroglitazar act on the PPAR. These lowers the TG, LDL-c, FPG, PPG, HbA1C, ApoB and ALT. 

Saraglitazar is an investigational new drug in the United State and is currently in Phase 2 clinical trial for the treatment of severe Hypertriglyceridemia and Non-Alcoholic steatohepatits. 

Non-Alcoholic Steatetohepatitis NASH:

The Zydus has initiated the 52 week phase 3 trial and reported good efficiency in animal model of NASH. It has also reported reduced steatosis, ballooning, inflammation and fibrosis in liver. 

Recomended Dose: 

The dose of Lipaglyn is 4 mg once a day.